In this episode, we take a look at some of the challenges that are encountered when trying to introduce digital to drug delivery devices, where the value and opportunities lie for digital, and what the future might hold for digital in combination devices.
Mark describes what could be a typical trajectory when considering adding a digital element to a drug delivery device, introducing where challenges might present themselves along a hypothetical timeline, contrasting with what might be a typical timeline for any pharmaceutical product. The reality of constantly evolving apps, boards, and software is very different from that of a 'regular' drug or biologic. The value - to patients, health care providers, industry, and many other stakeholders is also a critical aspect of including digital in drug delivery devices.
Mark goes on to describe the pros and cons associated with connected devices: the management of personal and clinical data, and the value that data can realise in enhancing patient experiences and optimising treatment and its outcomes. Mark also touches upon connected devices failures and their implications, and cites some of the key successes seen in this space to date with insulin delivery, and ways in which we can perhaps extend that success to other therapeutic areas. Mark speaks so fluently about this topic that you'll be left wanting more. Let us know if you want a sequel.